SCRIP ASKS…What Does 2021 Hold For Biopharma?
A broad survey of the industry's expectations for the year to come.
Every December, Scrip asks industry leaders and experts to share their expectations for the year to come. With responses from more than 200 professionals, Scrip Asks…What Does 2021 Hold For Biopharma? provides an unprecedented insight into the biopharma universe's collective crystal ball.
The full list of installments:
"COVID-19 is a great reminder and a testament that biopharma's core mission is to meet patient and society's needs." These words of Lihua Yu, president and chief data science officer of Eisai Co., Ltd.'s precision oncology subsidiary H3 Biomedicine, resonated time and again among the responses from the more than 200 industry leaders who answered our call to share predictions for 2021.
This third installment of our Scrip Asks… annual forecast series is therefore dedicated to perspectives that could be loosely grouped...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?